Scientists have developed a new method which identifies pancreatic cancer at an early stage by spotting its visible precursors with 97 percent certainty.
The method, which may be introduced within five years, is expected to minimize the risk of unnecessary surgery in the patients, New Scientist reported.
The researchers at The Sahlgrenska Academy, University of Gothenburg, can predict which pancreatic cysts constitute precursors to cancer and detect the presence of mucus protein, mucins, in the cystic fluid.
The new method, proteomics, has also been tested to analyze existing tumors, with about 90 percent certainty, and the scientists have been able to determine which tumors have already developed into cancers.
Professor Gunnar C. Hansson said the procedure can now measure biomarkers both quickly and exactly and requires minimal biomaterial, in this case 25 times less cyst fluid than conventional tumor marker analyses.
The study was published in Journal of the National Cancer Institute.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
